Physician profile
Michelle White
NPI 1265690598
$897.10
in general payments reported to CMS, 2019-2025
14 companies · $576 in 2025
The $576 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.83 · 2020: $15.10 · 2021: $14.15 · 2022: $20.60 · 2023: $29.14 · 2024: $189 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $163.92 | 2019-2025 | |
| Biotissue Holdings INC. | $133.96 | 2024-2025 | |
| Alcon Vision LLC | $103.80 | 2021-2025 | Rocklatan, Clareon, Tryptyr |
| Abbvie INC. | $102.52 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $91.52 | 2022-2025 | Tecnis Iol, Tecnis Iol |
| Dompe US, INC. | $85.84 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $81.97 | 2024-2025 | Ic-8 Apthera Iol, Vyzulta, Xiidra |
| Sandoz INC. | $32.74 | 2025 | Cimerli |
| Ocular Therapeutix, INC. | $22.01 | 2025 | Dextenza |
| Shire North American Group INC | $17.20 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $16.57 | 2025 | Xdemvy |
| Allergan, INC. | $15.10 | 2020 | |
| C. R. Bard, INC. & Subsidiaries | $15.07 | 2024 | Bard Urinary Drainage Bag |
| Eyevance Pharmaceuticals LLC | $14.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.